Site-initiated clinical trials are challenging, particularly with vulnerable populations like ICU patients.
Regarding changing practice: The trial's answer should be important enough that any intensivist treating such a patient would care about it. Examples of questions that probably aren't important enough are: (1) Is there a difference in ARDS outcome if the tidal volume is 4, 6, or 8 mL/kg?, (2) Is knee-high pneumatic compression inferior to thigh-high pneumatic compression for thromboembolism prophylaxis in anticoagulant-contraindicated patients?, and (3) Do piperacillin-tazobactam and cefepime have equivalent efficacy for empiric coverage of hospital-acquired infections? The first question probably has a patientspecific, non-generalizable answer; the second, with small "dose" differences has high risk of being a negative study; the third answer likely depends on local organisms, and The second criterion is important because if your site doesn't see enough patients, coordination with multiple centers and delay can imperil completion. Estimating sample size early for feasibility is important. For the ECCO2R proposal, an estimate for 30-day survival of such patients is 25%. To double survival to 50%, 2-sided p ¼ 0.05, with 80% power, sample size is 65/group, 130 patients altogether. For the ECPR proposal, an estimate without ECPR is 5% survival after an hour of CPR. To raise survival to 25%, 2-sided p ¼ 0.05, with 80% power, sample size is 58/group, 116 patients. These numbers may be practically achieved in some centers after 2-3 years, when the answers will still be pertinent.
The third criterion addresses whether the question is practical: Can a protocol fair to patients be devised and executed? For both ECCO2R and ECPR proposals, the protocols must (1) Establish criteria to assure no prolongation of life just to favor one unblinded group or another, and (2) Establish a process to assure uniform patient entrance and procedures among participating physicians and centers. Careful thought and collegial consultation at the start of study planning is important for helping ICU patients with your clinical research. Preparing the final study report similarly requires close attention and consultation
